{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:30:21Z","timestamp":1790692221495,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejphar.2017.09.043","type":"journal-article","created":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T14:45:22Z","timestamp":1506869122000},"page":"364-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":153,"special_numbering":"C","title":["The present and future of pharmacotherapy of Alzheimer\u2019s disease: A comprehensive review"],"prefix":"10.1016","volume":"815","author":[{"given":"Abhinav","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Anosi","family":"Patience","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.09.043_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nature.2016.21045","article-title":"Failed Alzheimer\u2019s trial does not kill leading theory of disease","volume":"540","author":"Abbott","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2017.09.043_bib2","unstructured":"AC Immune, 2017. AD Treatment and Prevention [WWW Document]. URL \u3008http:\/\/www.acimmune.com\/en\/ad-treatment-and-prevention\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib3","unstructured":"Accera Inc, 2017. AC-1204 A new hope in Alzheimer\u2019s disease [WWW Document]. URL \u3008http:\/\/www.accerapharma.com\/portfolio\/ac-1204\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib4","unstructured":"Adis Insight, 2017a. CPC 250 [WWW Document]. Springer International Publ. AG. URL \u3008http:\/\/adisinsight.springer.com\/drugs\/800043992\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib5","unstructured":"Adis Insight, 2017b. RG 6100 - [WWW Document]. Springer International Publ. AG. URL \u3008http:\/\/adisinsight.springer.com\/drugs\/800046712\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib6","unstructured":"Adis Insight, 2017c. ASP 3662 [WWW Document]. Springer International Publ. AG. URL \u3008http:\/\/adisinsight.springer.com\/drugs\/800040639\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib7","unstructured":"Adis Insight, 2017d. E 2027 [WWW Document]. Springer International Publ. AG. URL \u3008http:\/\/adisinsight.springer.com\/drugs\/800042285\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib8","unstructured":"Adis Insight, 2016. CPC 212 [WWW Document]. Springer International Publ. AG. URL \u3008http:\/\/adisinsight.springer.com\/drugs\/800043989\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib9","unstructured":"Adis Insight, 2015. INP 102 [WWW Document]. Springer International Publ. AG. URL \u3008http:\/\/adisinsight.springer.com\/drugs\/800043433\u3009 (accessed 5 January 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib10","unstructured":"AgeneBio, 2017. AGB101 for Amnestic Mild Cognitive Impairment (aMCI) [WWW Document]. URL \u3008http:\/\/www.agenebio.com\/pipeline\/agb101-for-amnestic-mild-cognitive-impairment-amci\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the alphase study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ejphar.2017.09.043_bib12","unstructured":"Alla Chem LLC, 2017. CNS Platform [WWW Document]. URL \u3008http:\/\/allachem.com\/pipeline\/cns-platform\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib13","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1523\/JNEUROSCI.18-09-03213.1998","article-title":"Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer\u2019s fibrils","volume":"18","author":"Alvarez","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2017.09.043_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/jmbi.1997.1245","article-title":"Acetylcholinesterase promotes the aggregation of amyloid-\u03b2-peptide fragments by forming a complex with the growing fibrils","volume":"272","author":"Alvarez","year":"1997","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib15","unstructured":"Alzforum, 2017. Epothilone D | ALZFORUM [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/epothilone-d\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib16","unstructured":"Alzforum, 2017a. Therapeutics Azeliragon [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/azeliragon\u3009 (accessed 5 January 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib17","unstructured":"Alzforum, 2017b. Therapeutics Bexarotene [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/bexarotene\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib18","unstructured":"Alzforum, 2017c. Therapeutics LY3002813 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/ly3002813\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib19","unstructured":"Alzforum, 2017d. Therapeutics MEDI1814 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/medi1814\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib20","unstructured":"Alzforum, 2017e. Therapeutics SAR228810 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/sar228810\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib21","unstructured":"Alzforum, 2017f. Therapeutics AGB101 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/agb101\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib22","unstructured":"Alzforum, 2017g. Therapeutics PF-06648671 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/pf-06648671\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib23","unstructured":"Alzforum, 2017h. Therapeutics PF-06751979 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/pf-06751979\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib24","unstructured":"Alzforum, 2017i. Therapeutics Anavex 2-73 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/anavex-2-73\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib25","unstructured":"Alzforum, 2017j. Therapeutics TPI 287 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/tpi-287\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib26","unstructured":"Alzforum, 2017k. Therapeutics AC-1204 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/ac-1204\u3009 (accessed 5 January 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib27","unstructured":"Alzforum, 2017l. Therapeutics Nilvadipine [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/nilvadipine\u3009 (accessed 5 January 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib28","unstructured":"Alzforum, 2017m. Therapeutics PF-05251749 [WWW Document]. URL \u3008http:\/\/www.alzforum.org\/therapeutics\/pf-05251749\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib29","unstructured":"Alzheimer\u2019s Association, 2017. Stages of Alzheimer\u2019s and Symptoms | Alzheimer\u2019s Association [WWW Document]. URL \u3008http:\/\/www.alz.org\/alzheimers_disease_stages_of_alzheimers.asp\u3009 (accessed 3 June 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib30","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.jalz.2014.02.001","article-title":"2014 Alzheimer\u2019s disease facts and figures","volume":"10","author":"Alzheimer\u2019s Association","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ejphar.2017.09.043_bib31","unstructured":"Alzheon Preserving Future Memories, 2017. Pipeline [WWW Document]. URL \u3008http:\/\/alzheon.com\/alzheon-pipeline\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib32","doi-asserted-by":"crossref","unstructured":"Amaducci, L., Crook, T.H., Lippi, A., Bracco, L., Baldereschi, M., Latorraca, S., Piersanti, P., Tesco, G., Sorbi, S., 1986. Use of Phosphatidylserine in Alzheimer\u2019s Disease 245\u2013249. doi:10.1111\/j.1749-6632.1991.tb00227.x.","DOI":"10.1111\/j.1749-6632.1991.tb00227.x"},{"key":"10.1016\/j.ejphar.2017.09.043_bib33","unstructured":"Amgen, 2017. Pipeline [WWW Document]. URL \u3008http:\/\/www.amgenpipeline.com\/pipeline\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib34","doi-asserted-by":"crossref","first-page":"40753","DOI":"10.1038\/srep40753","article-title":"Vanillic acid attenuates A\u03b21-42-induced oxidative stress and cognitive impairment in mice","volume":"7","author":"Amin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2017.09.043_bib35","unstructured":"Anavex, 2017. Pipeline [WWW Document]. URL \u3008http:\/\/www.anavex.com\/pipeline\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib36","unstructured":"Anavex Life Sciences Corp, 2017a. ANAVEX 2-73 [WWW Document]. URL \u3008http:\/\/www.anavex.com\/pipeline\/anavex-2-73\/\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib37","unstructured":"Anavex Life Sciences Corp, 2017b. ANAVEX PLUS [WWW Document]. URL \u3008http:\/\/www.anavex.com\/pipeline\/anavex-plus\/\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib38","unstructured":"ArcherPharma, 2017. Products and Research [WWW Document]. URL \u3008http:\/\/www.archerpharma.com\/products&research.html\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib39","unstructured":"Astellas Pharma US INC, 2017. R and D Pipeline."},{"key":"10.1016\/j.ejphar.2017.09.043_bib40","unstructured":"Avanir Pharmaceuticals, 2017. Product Pipeline Avanir Pharmaceuticals [WWW Document]. URL \u3008http:\/\/www.avanir.com\/science\/pipeline\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib41","unstructured":"Avanir Pharmaceuticals, 2015. Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer\u2019s Disease [WWW Document]. URL \u3008https:\/\/www.avanir.com\/press\/avanir-pharmaceuticals-announces-initiation-phase-iii-trial-avp-786-agitation-patients\u3009 (accessed 4 February 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib42","unstructured":"Avineuro Pharmaceuticals, I., 2017. Pipeline [WWW Document]. URL \u3008http:\/\/www.avineuro.com\/pipeline\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib43","unstructured":"Axsome Therapeutics, 2017a. Overview andPipeline [WWW Document]. URL \u3008http:\/\/axsome.com\/company\/overview-pipeline\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib44","unstructured":"Axsome Therapeutics, 2017b. Treatment Resistant Depression (TRD) [WWW Document]. URL \u3008http:\/\/axsome.com\/axs-05\/treatment-resistant-depression-trd\/\u3009 (accessed 4 February 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib45","unstructured":"AZ Therapies Inc, 2017. ALZT-OP1 treatment for Alzheimer\u2019s Disease [WWW Document]. URL \u3008http:\/\/aztherapies.com\/aztherapies-programs-and-drug-pipeline\/our-alzheimers-program-and-our-product-pipeline\/alzt-op1-alzheimers-treatment\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib46","first-page":"339","article-title":"Effect of Tinospora cordifolia on learning and memory in normal and memory deficit rats","volume":"34","author":"Bairy","year":"2002","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib47","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40266-013-0108-6","article-title":"Successes and failures for drugs in late-stage development for Alzheimer\u2019s disease","volume":"30","author":"Berk","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejphar.2017.09.043_bib48","unstructured":"Biogen, 2017. Research Pipeline [WWW Document]. URL \u3008https:\/\/www.biogen.com\/en_us\/research-pipeline\/biogen-pipeline.html\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib49","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0955-2863(02)00205-X","article-title":"Nutritional approaches to combat oxidative stress in Alzheimer\u2019s disease","volume":"13","author":"Butterfield","year":"2002","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.ejphar.2017.09.043_bib50","unstructured":"Green, Carol, Tanga, Mary, 2014. Development of an Agonist of the TGF-Beta Signaling Pathway to Treat Alzheimer\u2019s Disease | SRI International [WWW Document]. URL \u3008https:\/\/www.sri.com\/work\/publications\/development-agonist-tgf-beta-signaling-pathway-treat-alzheimers-disease-0\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib51","unstructured":"Centers for Disease Control and Prevention, 2017. Leading Causes of Death [WWW Document]. CDC. URL \u3008https:\/\/www.cdc.gov\/nchs\/fastats\/leading-causes-of-death.htm\u3009 (accessed 4 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib52","unstructured":"CereSpir Inc, 2016. CSP-1103 Overview [WWW Document]. URL \u3008http:\/\/www.cerespir.com\/csp-1103-overview\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4103\/0976-9668.117025","article-title":"Beneficial effect of aqueous root extract of Glycyrrhiza glabra on learning and memory using different behavioral models: an experimental study","volume":"4","author":"Chakravarthi","year":"2013","journal-title":"J. Nat. Sci. Biol. Med"},{"key":"10.1016\/j.ejphar.2017.09.043_bib54","unstructured":"Chase Pharmaceuticals, 2017. Pipeline [WWW Document]. URL \u3008http:\/\/www.chasepharmaceuticals.com\/pipeline\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib55","unstructured":"Coticebio, 2017. Pipeline [WWW Document]. URL \u3008www.corticebio.com\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib56","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1055\/s-2008-1034319","article-title":"Effect of glabridin from Glycyrrhiza glabra on learning and memory in mice","volume":"74","author":"Cui","year":"2008","journal-title":"Planta Med."},{"key":"10.1016\/j.ejphar.2017.09.043_bib57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejphar.2017.09.043_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2017.09.043_bib59","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.mehy.2008.12.029","article-title":"Getting the iron out: phlebotomy for Alzheimer\u2019s disease?","volume":"72","author":"Dwyer","year":"2009","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejphar.2017.09.043_bib60","unstructured":"Eisai, 2017. Major R and D Pipeline."},{"key":"10.1016\/j.ejphar.2017.09.043_bib61","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/0960327112467040","article-title":"Serrapeptase and nattokinase intervention for relieving Alzheimer\u2019s disease pathophysiology in rat model","volume":"32","author":"Fadl","year":"2013","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900014164","article-title":"The interplay of neurotransmitters in Alzheimer\u2019s disease","volume":"10","author":"Francis","year":"2005","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejphar.2017.09.043_bib63","unstructured":"Genentech, 2017. Pipeline [WWW Document]. URL \u3008https:\/\/www.gene.com\/medical-professionals\/pipeline\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib64","unstructured":"GlaxoSmithKline, 2016. Pipeline."},{"key":"10.1016\/j.ejphar.2017.09.043_bib65","unstructured":"GliaCure, 2017. GliaCure\u2019s Approach [WWW Document]. URL \u3008https:\/\/gliacure.com\/about-glia-cure\/our-approach\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib66","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cbi.2010.05.002","article-title":"Galangin, a flavonol derived from Rhizoma Alpiniae Officinarum, inhibits acetylcholinesterase activity in vitro","volume":"187","author":"Guo","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejphar.2017.09.043_bib67","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejphar.2016.07.013","article-title":"PASS assisted prediction and pharmacological evaluation of hesperidin against scopolamine induced amnesia in mice","volume":"789","author":"Habibyar","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2680409","article-title":"The therapeutic potential of Rosemary (Rosmarinus officinalis) Diterpenes for Alzheimer\u2019s disease","volume":"2016","author":"Habtemariam","year":"2016","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"10.1016\/j.ejphar.2017.09.043_bib69","first-page":"23","article-title":"Antiamnesic effects of walnuts consumption on scopolamine-induced memory impairments in rats","volume":"6","author":"Harandi","year":"2015","journal-title":"Basic Clin. Neurosci."},{"issue":"80","key":"10.1016\/j.ejphar.2017.09.043_bib70","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2017.09.043_bib71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1743-7075-6-31","article-title":"Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer\u2019s disease: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"6","author":"Henderson","year":"2009","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.ejphar.2017.09.043_bib72","doi-asserted-by":"crossref","first-page":"457","DOI":"10.5142\/jgr.2011.35.4.457","article-title":"Improvement of cognitive deficit in Alzheimer\u2019s disease patients by long term treatment with korean red ginseng","volume":"35","author":"Heo","year":"2011","journal-title":"J. Ginseng Res."},{"key":"10.1016\/j.ejphar.2017.09.043_bib73","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/ptr.3178","article-title":"Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-amyloid-induced toxicity in PC12 cells","volume":"24","author":"Hoi","year":"2010","journal-title":"Phytother. Res."},{"key":"10.1016\/j.ejphar.2017.09.043_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ptr.1280","article-title":"Plants with traditional uses and activities, relevant to the management of Alzheimer\u2019s disease and other cognitive disorders","volume":"17","author":"Howes","year":"2003","journal-title":"Phytother. Res."},{"key":"10.1016\/j.ejphar.2017.09.043_bib75","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMsa1204629","article-title":"Monetary costs of Dementia in the United States","volume":"368","author":"Hurd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2017.09.043_bib76","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-2009-1092","article-title":"Why did tarenflurbil fail in Alzheimer\u2019s disease?","volume":"17","author":"Imbimbo","year":"2009","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2017.09.043_bib77","unstructured":"Impel Neuropharma,\u00a02016. Alzheimer\u2019s Treatment [WWW Document]. URL \u3008http:\/\/impelnp.com\/treatments\/alzheimers-treatment\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib78","unstructured":"Janssen, 2017. Our Fight Against Alzheimer\u2019s [WWW Document]. URL \u3008http:\/\/www.janssen.com\/neuroscience\/our-fight-against-alzheimers-reasons-for-hope\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib79","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s12272-014-0492-4","article-title":"BACE1 and cholinesterase inhibitory activities of Nelumbo nucifera embryos","volume":"38","author":"Jung","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejphar.2017.09.043_bib80","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0006-2952(00)00330-0","article-title":"Kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolserine","volume":"60","author":"Kamal","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib81","unstructured":"Kelly, R.B., Bumol, T.F., Chi-Kin, C., Demattos, R.B., Ryan John, H., Uma, K., Jirong, L., Peter, C.M., 2015. Pegylated amyloid beta fab (EP 2842967 A1) [WWW Document]. URL \u3008http:\/\/www.google.com\/patents\/EP2842967A1?Cl=en\u3009 (accessed 27 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib82","doi-asserted-by":"crossref","first-page":"d.","DOI":"10.1155\/2014\/869831","article-title":"Cognitive enhancing and neuroprotective effect of the embryo of the Nelumbo nucifera seed","volume":"2014","author":"Kim","year":"2014","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"10.1016\/j.ejphar.2017.09.043_bib83","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1381612043386392","article-title":"NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer\u2019s and vascular dementia","volume":"10","author":"Koch","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2017.09.043_bib84","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/0253-7613.66841","article-title":"Efficacy study of prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats","volume":"42","author":"Kulkarni","year":"2010","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib85","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4103\/0253-7613.161274","article-title":"Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin","volume":"47","author":"Kumar","year":"2015","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib86","first-page":"3069","article-title":"Kinetics of acetylcholinesterase inhibition by an aqueous extract of Withania somnifera roots","volume":"2","author":"Kumar","year":"2011","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/j.ejphar.2017.09.043_bib87","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/WAD.0b013e31816c92e6","article-title":"Panax ginseng enhances cognitive performance in Alzheimer disease","volume":"22","author":"Lee","year":"2008","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.ejphar.2017.09.043_bib88","unstructured":"Lilly, 2017. Clinical Development Pipeline [WWW Document]. URL \u3008https:\/\/www.lilly.com\/pipeline\/index.html\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/ageing\/afj083","article-title":"Comparative analysis of mortality in patients with Alzheimer\u2019s disease treated with donepezil or galantamine","volume":"35","author":"L\u00f3pez-Pousa","year":"2006","journal-title":"Age Ageing"},{"key":"10.1016\/j.ejphar.2017.09.043_bib90","unstructured":"Lundbeck, 2017. Pipeline [WWW Document]. URL \u3008www.investor.lundbeck.com\/pipeline.cfm\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib91","series-title":"Cochrane Database of Systematic Reviews","article-title":"Tramiprosate (Alzhemed) for Alzheimer\u2019s disease","author":"Malouf","year":"2009"},{"key":"10.1016\/j.ejphar.2017.09.043_bib92","unstructured":"Mansuo, L.H., Jirong, L., David, D., Alberto, A., 2016. Antibodies to tau and uses thereof US 20160251420 A1 [WWW Document]. URL \u3008http:\/\/google.com\/patents\/US20160251420?Cl=pt\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib93","first-page":"606","article-title":"In vitro evaluation of anti-Alzheimer effects of dry ginger (Zingiber officinale Roscoe) extract","volume":"52","author":"Mathew","year":"2014","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib94","unstructured":"Mattia, A., Antonia Mattia, D., Cho, S., Healthcare, E., 1997. GRN 000637 Subject: GRAS Notice for Phosphatidylserine derived from Soy Lecithin GRAS EXEMPTION CLAIM for BioPS \u00ae Manufactured by ECA Healthcare, Federal Register."},{"key":"10.1016\/j.ejphar.2017.09.043_bib95","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1365-2125.1999.00026.x","article-title":"Acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"48","author":"McGleenon","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib96","unstructured":"MedImmune, 2017. Pipeline [WWW Document]. URL \u3008https:\/\/www.medimmune.com\/our-science\/pipeline.html\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib97","article-title":"New acetylcholinesterase inhibitors for alzheimer\u2019s disease","volume":"2012","author":"Mehta","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2017.09.043_bib98","unstructured":"Merciapharma, 2017. Alzheimer\u2019s Disease (MER5101) \u2013 Product Pipeline [WWW Document]. URL \u3008http:\/\/merciapharma.com\/?Page_id=90\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib99","unstructured":"MerciaPharma, 2014. Alzheimer\u2019s Disease (MER5101) [WWW Document]. URL \u3008http:\/\/merciapharma.com\/?Page_id=90\u3009 (accessed 27 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib100","unstructured":"Merck, 2017. Pipeline [WWW Document]. URL \u3008http:\/\/www.merck.com\/research\/index.html#Pipeline\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib101","unstructured":"Metabolic Solutions Development, 2017. Clinical Therapeutics (MSDC-0160) [WWW Document]. URL \u3008http:\/\/www.msdrx.com\/pipeline\/msdc-0160\u3009 (accessed 5 January 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib102","unstructured":"Metabolic Solutions Development, 2016. Pipeline [WWW Document]. URL \u3008http:\/\/www.msdrx.com\/pipeline\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/0972-2327.40220","article-title":"The effect of curcumin (turmeric) on Alzheimer\u2019s disease: an overview introduction Curcumin and Alzheimer\u2019s disease epidemiological studies curcumin as an anti inflammatory in Alzheimer\u2019s Curcumin as an anti-oxidant","volume":"11","author":"Mishra","year":"2008","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/153331750502000206","article-title":"Memantine: targeting glutamate excitotoxicity in Alzheimer\u2019s disease and other dementias","volume":"20","author":"Molinuevo","year":"2005","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"10.1016\/j.ejphar.2017.09.043_bib105","unstructured":"Nanotherapeutics, 2016. Pipeline [WWW Document]. URL \u3008http:\/\/www.nanotherapeutics.com\/pipeline\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib106","unstructured":"NeuroGenetic Pharmaceuticals, 2017. Products and Technology [WWW Document]. URL \u3008http:\/\/neurogeneticpharmaceuticals.com\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib107","unstructured":"NeutropeBioscience, 2017. ProductDevelopment [WWW Document]. URL \u3008http:\/\/www.neurotropebioscience.com\/Welcome_to_Neurotrope_BioScience\/ProductDevelopment-DevPipeline.html\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib108","unstructured":"NIH, 2017. Search of: Alzheimer\u2019s disease\/. - Results on Map - ClinicalTrials.gov [WWW Document]. URL \u3008https:\/\/clinicaltrials.gov\/ct2\/results\/map?Term=Alzheimer%27s+disease%2F\u3009. (accessed 22 February 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib109","unstructured":"NIH National Institute on Aging, 2017a. About Alzheimer\u2019s Disease: Diagnosis | National Institute on Aging [WWW Document]. URL \u3008https:\/\/www.nia.nih.gov\/alzheimers\/topics\/diagnosis\/\u3009 (accessed 3 June 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib110","unstructured":"NIH National Institute on Aging, 2017b. About Alzheimer\u2019s Disease: Treatment | National Institute on Aging [WWW Document]. URL \u3008https:\/\/www.nia.nih.gov\/alzheimers\/topics\/treatment\u3009 (accessed 3 June 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib111","unstructured":"NILVAD, 2017. New treatment in Alzheimer\u2019s disease [WWW Document]. URL \u3008https:\/\/www.nilvad.eu\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib112","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00401-014-1371-2","article-title":"Tau aggregation and its interplay with amyloid-\u03b2","volume":"129","author":"Nisbet","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib113","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/0976-3147.80102","article-title":"Effect of plant extracts on Alzheimer\u2032s disease: an insight into therapeutic avenues","volume":"2","author":"Obulesu","year":"2011","journal-title":"J. Neurosci. Rural Pract."},{"key":"10.1016\/j.ejphar.2017.09.043_bib114","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/156720512801322564","article-title":"N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer\u2019s disease, vascular dementia and Parkinson\u2019s disease","volume":"9","author":"Olivares","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2017.09.043_bib115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/msj.20157","article-title":"Neuropathology of Alzheimer\u2019s disease","volume":"77","author":"Perl","year":"2010","journal-title":"Mt Sinai J. Med."},{"key":"10.1016\/j.ejphar.2017.09.043_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/734956","article-title":"The complexity of Sporadic Alzheimer\u2019s disease pathogenesis: the role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction","volume":"2012","author":"Perrone","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2017.09.043_bib117","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/(SICI)1099-1166(199612)11:12<1063::AID-GPS532>3.0.CO;2-1","article-title":"European herbs with cholinergic activities: potential in dementia therapy","volume":"11","author":"Perry","year":"1996","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ejphar.2017.09.043_bib118","unstructured":"Pfizer Pipeline, 2010. [WWW Document]. URL papers3:\/\/publication\/uuid\/3CB6CA62-4D48-4E91-9FED-CD642404488F (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib119","doi-asserted-by":"crossref","first-page":"e31921","DOI":"10.1371\/journal.pone.0031921","article-title":"Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits Amyloid-\u03b2-mediated Alzheimer\u2019s disease-associated pathogenesis in vitro and in vivo","volume":"7","author":"Pi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2017.09.043_bib120","unstructured":"QR Pharma Inc, 2017a. CLINICAL [WWW Document]. URL \u3008http:\/\/qrpharma.com\/clinical\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib121","unstructured":"QR Pharma Inc, 2017b. POSIPHEN\u00ae | THE MOLECULE [WWW Document]. URL \u3008http:\/\/qrpharma.com\/innovation\/\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib122","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.phrs.2003.12.027","article-title":"Acetylcholinesterase inhibitors: novel activities of old molecules","volume":"50","author":"Racchi","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2017.09.043_bib123","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","article-title":"A phase II trial of huperzine A in mild to moderate Alzheimer disease","volume":"76","author":"Rafii","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2017.09.043_bib124","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/0973-8258.49368","article-title":"Role of Ocimum sanctum in the experimental model of Alzheimer\u2032s disease in rats","volume":"3","author":"Raghavendra","year":"2009","journal-title":"Int. J. Green. Pharm."},{"key":"10.1016\/j.ejphar.2017.09.043_bib125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/alzrt125","article-title":"Ayurvedic medicinal plants for Alzheimer\u2019s disease: a review","volume":"4","author":"Rao","year":"2012","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejphar.2017.09.043_bib126","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2017.09.043_bib127","unstructured":"Resverlogix Corp, 2017a. Alzheimer\u2019s Disease [WWW Document]. URL \u3008http:\/\/www.resverlogix.com\/programs\/rvx-208-clinical-development\/apoa-i-hdl-reverse-cholesterol-transport.html#.WL3AnhKGPUp\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib128","unstructured":"Resverlogix Corp, 2017b. BET Inhibition [WWW Document]. URL \u3008https:\/\/www.resverlogix.com\/programs\/rvx-208-moa\/BET_Inhibition.html#.WQYoa4mGN0s\u3009 (accessed 30 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib129","unstructured":"Rexceptor, 2017. Pipeline [WWW Document]. URL \u3008http:\/\/www.rexceptor.com\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib130","unstructured":"Sanofi, 2017. R and D Pipeline - Pharma and Vaccines."},{"key":"10.1016\/j.ejphar.2017.09.043_bib131","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1515\/znc-2010-7-804","article-title":"Acetylcholinesterase inhibitory activity of uleine from Himatanthus lancifolius","volume":"65","author":"Seidl","year":"2010","journal-title":"Z. Naturforsch. C"},{"key":"10.1016\/j.ejphar.2017.09.043_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1567205013666161026150455","article-title":"Uleine disrupts key enzymatic and non-enzymatic biomarkers that leads to Alzheimer\u2019s disease","volume":"14","author":"Seidl","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2017.09.043_bib133","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.3390\/nu7075246","article-title":"Ferulic acid: a hope for Alzheimer???S disease therapy from plants","volume":"7","author":"Sgarbossa","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.ejphar.2017.09.043_bib134","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ptr.854","article-title":"Protective effect of Acorus calamus against acrylamide induced neurotoxicity","volume":"16","author":"Shukla","year":"2002","journal-title":"Phytother. Res."},{"key":"10.1016\/j.ejphar.2017.09.043_bib135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejmech.2013.09.050","article-title":"Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection","volume":"70","author":"Singh","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2017.09.043_bib136","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/2231-0738.95927","article-title":"Medicinal plants with a potential to treat Alzheimer and associated symptoms","volume":"2","author":"Singhal","year":"2012","journal-title":"Int. J. Nutr. Pharmacol. Neurol. Dis."},{"key":"10.1016\/j.ejphar.2017.09.043_bib137","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s40242-016-5347-8","article-title":"Studies on the interaction between vanillin and \u03b2-Amyloid protein via fluorescence spectroscopy and atomic force microscopy","volume":"32","author":"Song","year":"2016","journal-title":"Chem. Res. Chin. Univ."},{"key":"10.1016\/j.ejphar.2017.09.043_bib138","unstructured":"Suven, 2017. Suven Discovery Pipeline."},{"key":"10.1016\/j.ejphar.2017.09.043_bib139","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bbadis.2013.09.010","article-title":"The Alzheimer\u2019s disease mitochondrial cascade hypothesis: progress and perspectives","volume":"1842","author":"Swerdlow","year":"2014","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2017.09.043_bib140","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ageing\/afl027","article-title":"Acetylcholinesterase inhibitors for Alzheimer\u2019s disease: anti-inflammatories in acetylcholine clothing!","volume":"35","author":"Tabet","year":"2006","journal-title":"Age Ageing"},{"key":"10.1016\/j.ejphar.2017.09.043_bib141","unstructured":"Takeda, 2017. Research Pipeline."},{"key":"10.1016\/j.ejphar.2017.09.043_bib142","unstructured":"TauRx - A leader in Alzheimer\u2019s disease research, 2016. LMTX \u00ae for Alzheimer\u2019s [WWW Document]. URL \u3008http:\/\/www.taurx.com\/lmtx-for-alzheimers.html\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib143","unstructured":"Tetra Discovery Partners, 2017. Clinical Trials for Memory Loss Treatment [WWW Document]. URL \u3008http:\/\/tetradiscovery.com\/pipeline\/\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib144","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2217\/cpr.12.3","article-title":"Use of medical foods and nutritional approaches in the treatment of AD","volume":"9","author":"Thaipisuttikul","year":"2012","journal-title":"Clin. Pr."},{"key":"10.1016\/j.ejphar.2017.09.043_bib145","unstructured":"Transition Therapeutics Inc, 2017. Product Pipeline [WWW Document]. URL \u3008http:\/\/www.transitiontherapeutics.com\/technology\/pipeline.php\u3009 (accessed 3 July 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib146","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0378-8741(90)90065-2","article-title":"Central nervous system studies on an ethanol extract of Acorus calamus rhizomes","volume":"28","author":"Vohora","year":"1990","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2017.09.043_bib147","unstructured":"World Health Organization, 2016. Dementia Fact Sheet [WWW Document]. WHO. URL \u3008http:\/\/www.who.int\/mediacentre\/factsheets\/fs362\/en\/\u3009 (accessed 4 April 2017)."},{"key":"10.1016\/j.ejphar.2017.09.043_bib148","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/dot.2006.42.5.973584","article-title":"Tramiprosate","volume":"42","author":"Wright","year":"2006","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejphar.2017.09.043_bib149","doi-asserted-by":"crossref","unstructured":"Yao, E.C., Xue, L., 2014. Advances in Alzheimer\u2019s Disease Therapeutic Effects of Curcumin on Alzheimer\u2019s Disease 3, 145\u2013159. doi:10.4236\/aad.2014.34014.","DOI":"10.4236\/aad.2014.34014"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917306271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917306271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T04:40:29Z","timestamp":1570164029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917306271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":149,"alternative-id":["S0014299917306271"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.09.043","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The present and future of pharmacotherapy of Alzheimer\u2019s disease: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.09.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}